These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 9245910

  • 1. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects.
    Taskintuna I, Banker AS, Rao NA, Wiley CA, Flores-Aguilar M, Munguia D, Bergeron-Lynn G, De Clercq E, Keefe K, Freeman WR.
    Exp Eye Res; 1997 May; 64(5):795-806. PubMed ID: 9245910
    [Abstract] [Full Text] [Related]

  • 2. Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes.
    Banker AS, De Clercq E, Taskintuna I, Keefe KS, Bergeron-Lynn G, Freeman WR.
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1233-42. PubMed ID: 9620084
    [Abstract] [Full Text] [Related]

  • 3. Effects of topical and subconjunctival cidofovir (HPMPC) in an animal model.
    Banker AS, Bergeron-Lynn G, Keefe KS, De Clercq E, Taskintuna I, Freeman WR.
    Curr Eye Res; 1998 Jun; 17(6):560-6. PubMed ID: 9663845
    [Abstract] [Full Text] [Related]

  • 4. Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in Guinea pigs.
    Lu S, Cheng L, Hostetler KY, Koh HJ, Beadle JR, Davidson MC, Freeman WR.
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):205-9. PubMed ID: 15969637
    [Abstract] [Full Text] [Related]

  • 5. Intraocular properties of an alkoxyalkyl derivative of cyclic 9-(S)-(3-hydroxyl-2-phosphonomehoxypropyl) adenine, an intravitreally injectable anti-HCMV drug in rabbit and guinea pig.
    Tammewar AM, Cheng L, Hostetler KY, Falkenstein I, Beadle JR, Barron EC, Kozak I, Freeman WR.
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):433-44. PubMed ID: 17900229
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
    Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, de Clercq E, Freeman WR.
    Ophthalmology; 1995 Apr; 102(4):533-42; discussion 542-3. PubMed ID: 7724170
    [Abstract] [Full Text] [Related]

  • 7. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS).
    Taskintuna I, Rahhal FM, Rao NA, Wiley CA, Mueller AJ, Banker AS, De Clercq E, Arevalo JF, Freeman WR.
    Ophthalmology; 1997 Nov; 104(11):1827-36; discussion 1836-7. PubMed ID: 9373113
    [Abstract] [Full Text] [Related]

  • 8. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
    Taskintuna I, Rahhal FM, Arevalo JF, Munguia D, Banker AS, De Clercq E, Freeman WR.
    Ophthalmology; 1997 Jun; 104(6):1049-57. PubMed ID: 9186448
    [Abstract] [Full Text] [Related]

  • 9. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.
    Banker AS, Arevalo JF, Munguia D, Rahhal FM, Ishimoto B, Berry C, De Clercq E, Ochabski R, Taskintuna I, Freeman WR.
    Am J Ophthalmol; 1997 Aug; 124(2):168-80. PubMed ID: 9262540
    [Abstract] [Full Text] [Related]

  • 10. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.
    Dolnak DR, Munguia D, Wiley CA, De Clercq E, Bergeron-Lynn GL, Boscher C, Connor JD, Sherwood C, Capparelli E, Armani R.
    Invest Ophthalmol Vis Sci; 1992 Apr; 33(5):1557-63. PubMed ID: 1559752
    [Abstract] [Full Text] [Related]

  • 11. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.
    Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA.
    Curr Eye Res; 1996 May; 15(5):569-76. PubMed ID: 8670758
    [Abstract] [Full Text] [Related]

  • 12. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.
    Chavez-de la Paz E, Arevalo JF, Kirsch LS, Munguia D, Rahhal FM, De Clercq E, Freeman WR.
    Ophthalmology; 1997 Mar; 104(3):539-44. PubMed ID: 9082286
    [Abstract] [Full Text] [Related]

  • 13. Effect of partial retinal destruction and gliosis on the intravitreal pharmacokinetics of HPMPC.
    Kim JW, el-Haig W, Capparelli EV, Besen G, Connor JD, Freeman WR.
    Retina; 1995 Mar; 15(6):513-7. PubMed ID: 8747447
    [Abstract] [Full Text] [Related]

  • 14. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
    Kuppermann BD, Assil KK, Vuong C, Besen G, Wiley CA, De Clercq E, Bergeron-Lynn G, Connor JD, Pursley M, Munguia D, Freeman WR.
    J Infect Dis; 1996 Jan; 173(1):18-23. PubMed ID: 8537656
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis.
    Rahhal FM, Arevalo JF, Munguia D, Taskintuna I, Chavez de la Paz E, Azen SP, Freeman WR.
    Ophthalmology; 1996 Jul; 103(7):1078-83. PubMed ID: 8684797
    [Abstract] [Full Text] [Related]

  • 16. [Intravitreal injection of cidofovir in cytomegalovirus retinitis].
    Kersten A, Althaus C, Hudde T, Pascha G, Schweykart N, Sundmacher R.
    Ophthalmologe; 1998 Sep; 95(9):602-6. PubMed ID: 9793381
    [Abstract] [Full Text] [Related]

  • 17. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E, Del Sole MJ, Torbidoni A, Fandino A, Asprea M, Croxatto JO, Chantada GL, Bramuglia GF, Schaiquevich P.
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [Abstract] [Full Text] [Related]

  • 18. Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.
    Wang H, Chhablani J, Freeman WR, Beadle JR, Hostetler KY, Hartmann K, Conner L, Aldern KA, Pearson L, Cheng L.
    Invest Ophthalmol Vis Sci; 2011 Dec 09; 52(13):9391-6. PubMed ID: 22058340
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.
    Cheng L, Hostetler KY, Lee J, Koh HJ, Beadle JR, Bessho K, Toyoguchi M, Aldern K, Bovet JM, Freeman WR.
    Invest Ophthalmol Vis Sci; 2004 Nov 09; 45(11):4138-44. PubMed ID: 15505067
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF, Tsourdou A, Tzatzarakis MN, Tsika C, Charisis S, Naoumidi I, Plainis S, Tsilimbaris MK.
    J Ocul Pharmacol Ther; 2013 Sep 09; 29(7):627-32. PubMed ID: 23556534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.